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doi:10.1016/j.jmii.2011.12.019Background/purpose: The relationship between fluoroquinolone resistance in Escherichia coli
isolates causing nosocomial infection and hospital antibiotic consumption were investigated.
Restriction of levofloxacin use was implemented to control the incidence of fluoroquinolone-
resistant E coli in the hospital.
Methods: The study was conducted from January 2004 to December 2010. Antimicrobial agent
consumption was obtained from the pharmacy computer system and presented as the defined
daily doses per 1000 patient-days every 6 months. The incidence of fluoroquinolone-resistant E
coli isolates causing nosocomial infections was obtained from the Department of Infection
Control every 6 months. An antimicrobial stewardship program, restricting levofloxacain use,
was implemented in July 2007.
Results: The incidence of fluoroquinolone-resistant E coli causing nosocomial infections was
significantly correlated with fluoroquinolone usage (p Z 0.005), but not with the use of third-
or fourth-generation cephalosporins, piperacillin-tazobactam, or carbapenems. Parenteral
(p Z 0.002), oral (p Z 0.018), and total levofloxacin (p Z 0.001) use were significantlyInfection Diseases, Department of Internal Medicine, Taipei Medical University Hospital, No. 252,
.
om.tw (Y.-J. Lee).
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commons.org/licenses/by-nc-nd/4.0/).
Levofloxacin use and fluoroquinolone-resistant E coli 425correlated with the extent of fluoroquinolone resistance. With a reduction of levofloxacin use,
a decrease of the incidence of fluoroquinolone resistance in E coli isolates was observed.
Conclusion: There is a significant correlation between levofloxacin use and the incidence of
nosocomial fluoroquinolone-resistant E coli isolates. The incidence of fluoroquinolone-
resistant E coli could be reduced by limiting levofloxacin consumption.
Copyright ª 2011, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
Escherichia coli is a common infection pathogen associated
with both community acquired and nosocomial infections.
Antibiotic resistance among E coli isolates continues to
increase, limiting the choices of antibiotics available for
treating urinary tract infections.1 A high ratio, >20%, of
fluoroquinolone resistance among E coli uropathogens has
been reported in several countries.2 The frequency of
extended-spectrum-beta-lactamase (ESBL)-producing E coli
bacteremia has increased worldwide; thus the use of car-
bapenems has increased.3 The emergence of carbapene-
mases, Klebsiella pneumoniae carbapenemases (KPC) and
New Delhi metallo-beta-lactamase-1 (NDM-1), has also
been reported. The NDM-1-producing gene was identified in
Enterobacteriaceae, mainly in E coli and K pneumoniae.4
NDM-1-producing bacteria exhibited a high resistance rate
to other classes of antimicrobial agents, such as fluo-
roquinolones or aminoglycosides.5
Fluoroquinolones were introduced as an antibiotic group
in the 1980s.6 Because of their broad antimicrobial spec-
trum, excellent oral and parenteral bioavailability, and low
toxicity, fluoroquinolones have been widely prescribed to
patients with bacterial infections.7 Fluoroquinolone use in
hospitals is reportedly associated with the emergence of
resistance in a variety of bacteria, including Staphylococcus
aureus, Pseudomonas aeruginosa, and E coli.8 Antibiotic
use is considered to be the main factor contributing to
the emergence of resistance.6 In this study, we investigated
whether the incidence of nosocomial fluoroquinolone-
resistant E coli can be reduced by controlling fluo-
roquinolone use in the hospital.
Methods
Hospital setting
Taipei Medical University Hospital (TMUH) is a private,
tertiary care, university-affiliated, teaching hospital in
Taipei, Taiwan. Medical, surgical, neonatal, and pediatric
intensive care units and an emergency room are available
at this hospital. The number of beds available was 350 in
2004, 560 in 2008, and 702 in 2010. The study period was
from January 1, 2004 to December 31, 2010.
Bacterial isolates and susceptibility testing
The broth microdilution method (Phoenix; Becton Dick-
inson, Sparks, MD, USA) was used to determine theantimicrobial susceptibility of E coli isolates. Antimicrobial
susceptibility tests were performed according to the Clin-
ical and Laboratory Standards Institute (CLSI) guidelines.9
Moxifloxacin susceptibility data were not available during
the study period. Only the first E coli isolate from each
patient was included. Fluoroquinolone-resistant E coli was
defined as an E coli isolate exhibiting either intermediate
resistance or resistance to either ciprofloxacin or levo-
floxacin. According to the CLSI criteria,9 susceptibility
breakpoints for ciprofloxacin and levofloxacin for E coli
used in this study were 1 mg/L and 2 mg/L, respectively.
Susceptibility data for E coli isolates causing nosocomial
infections were collected from the Infection Control
Department; these data were obtained every 6 months.
Antibiotic consumption
Fluoroquinolones (ciprofloxacin, levofloxacin, or moxi-
floxacin), third-generation cephalosporins (ceftriaxone,
cefotaxime, flomoxef, ceftazidime, or cefoperazone),
fourth-generation cephalosporins (cefepime or cefpirome),
piperacillin-tazobactam, and carbapenems (ertapenem,
imipenem, or meropenem) can be prescribed to treat noso-
comial E coli infections at TMUH. Parenteral ciprofloxacin,
oral ciprofloxacin, and oral levofloxacin were available
throughout the study period. Parenteral levofloxacin was
available after January 2005, and parenteral moxifloxacin
between January 2004 and June 2005. Oral and parenteral
moxifloxacin were listed in pharmacy formulation from
January 2007. In patients with normal renal function, paren-
teral ciprofloxacin dose was 400 mg every 12 hours, whereas
the oral dose was 500 mg every 12 hours. Before 2007, the
suggested levofloxacain dose was 500 mg once daily paren-
terally and orally. After 2007, the suggested levofloxacin dose
was 750 mg once daily parenterally and orally. The suggested
moxifloxacin dose was 400 mg once daily parenterally and
orally.Antibioticutilizationwasexpressedasthedefineddaily
doses per 1000 patient-days (DDD/1000PD) every 6 months.
The Department of Infection Control at TMUH led the
antimicrobial stewardship program, which has restricted
the use of levofloxacin since July 2007. Thus, the period
from January 2004 to June 2007 was the preintervention
period, and July 2007 to December 2010 was the post-
intervention period.
Statistical analysis
Least-squares linear regression was used to examine
the univariate relationship between antibiotic use and
the incidence of fluoroquinolone-resistant E coli isolates
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426 H.-H. Wu et al.causing nosocomial infections. Correlation coefficients (r or
r2) were determined. We used independent t tests to
determine significant differences between the pre- and
postintervention periods A p-value of <0.05 was considered
statistically significant.
Results
During the study period, 647 E coli isolates causing noso-
comial infections were collected, and 222 isolates were
fluoroquinolone resistant (34.31%). The relationship
between the incidence of fluoroquinolone-resistant E coli
isolates and antibiotic prescriptions for nosocomial infec-
tions is shown in Table 1.
Least-squares linear regression analyses showed no
significant correlation between the incidence of
fluoroquinolone-resistant E coli and total consumption of
third-generation cephalosporins, fourth-generation cepha-
losporins, piperacillin- tazobactam, or carbapenems. Only
total fluoroquinolone consumption was significantly corre-
lated with the incidence of fluoroquinolone-resistant E coli
(p Z 0.005). We then analyzed clinical usage of individual
fluoroquinolone, and the results are shown in Fig. 1 and Table
2. Parenteral levofloxacin (p Z 0.002), oral levofloxacin
(p Z 0.018), and total levofloxacin usage (p Z 0.001) are
significantly correlated with the incidence of
fluoroquinolone-resistant E coli (Table 2). However, paren-
teral ciprofloxacin, oral ciprofloxacin, and total ciprofloxacin
usage are, although not significantly, correlated with the
incidence of fluoroquinolone-resistant E coli (pZ 0.30, 0.63,
0.21, respectively; Fig. 1). Parenteral moxifloxacin, oral
moxifloxacin, and total moxifloxacin usage are negatively
correlated with the incidence of fluoroquinolone-resistant E
coli, but this relationship was not statistically significant
(pZ 0.38, 0.42, 0.08, respectively; Fig. 1).
Under the antimicrobial stewardship program, levo-
floxacin prescription was restricted in the second half of
2007. Following this program, the use of all fluo-
roquinolones, except oral ciprofloxacin, was significantly
reduced, as shown in Table 3. Total levofloxacin use
decreased by 28.47% between the pre- and post-
intervention periods (mean  standard deviation
14.12  5.37 DDD/1000PD vs. 10.10  5.72 DDD/1000PD,
p Z 0.006). This change was accompanied by a significant
reduction in the incidence of fluoroquinolone-resistant E
coli, which was reduced from 0.255 to 0.201 isolates
recovered per 1000 patient-days (p Z 0.040).
Discussion
Before the early 1990s, resistance to fluoroquinolone was
rarely mentioned in clinical isolates of E coli,10 and emer-
gence of fluoroquinolone-resistant E coli has been reported
subsequently. Livermore et al observed an increasing prev-
alence of fluoroquinolone-resistant E coli in blood cultures
(0.8% in 1990 and 3.8% in 1999).11 Shigemura et al reported
that the rate of fluoroquinolone-resistant E coli increased
from 3.5% in 2000 to 30.8% in 2007.12 Fluoroquinolone use
appears to be associated with increasing numbers of
fluoroquinolone-resistant Enterobacteriaceae isolates.7 Lee
et al identified that fluoroquinolone resistance in P
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DC
y = -0.0168x + 0.259
r
2
 = 0.2575
p = 0.382
y = 0.0115x + 0.1817
r
2
 = 0.5529
p = 0.002
y = 0.0045x + 0.1821
r
2
 = 0.0904
p = 0.296
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0 2 4 6 8 10 12 14 16 18
DDD/1000 patient-days
In
ci
de
nc
e 
of
 
flu
or
oq
uin
olo
ne
-
re
si
st
an
t E
. 
c
o
li
parenteral moxifloxacin parenteral levofloxacin parenteral ciprofloxacin
y = -0.023x + 0.2485
r
2
 = 0.3334
p = 0.421
y = 0.009x + 0.1735
r
2
 = 0.3841
p = 0.018
y = 0.0055x + 0.1509
r
2
 = 0.0203
p = 0.627
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0 2 4 6 8 10 12 14 16 18
DDD/1000 patient-days
in
ci
de
ne
 o
f f
lu
or
oq
ui
no
lo
ne
-
re
si
st
an
t E
.c
o
li
oral moxifloxacin oral levofloxacin oral ciprofloxacin
y = -0.0122x + 0.2614
r
2
 = 0.364
p = 0.082
y = 0.007x + 0.1575
r
2
 = 0.6341
p = 0.001
y = 0.0053x + 0.0979
r
2
 = 0.1274
p = 0.21
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0 5 10 15 20 25 30 35
DDD/1000 patient-days
in
ci
de
nc
e 
of
 
flu
ro
qu
in
ol
on
e-
re
si
st
an
t E
. 
c
o
li
total moxifloxacin total levofloxacin total ciprofloxacin 
y = 0.0058x + 0.0119
r
2
 = 0.4937
p = 0.005
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0 10 20 30 40 50 60
DDD/1000 patient-days
in
ci
de
nc
e 
of
 
flu
or
oq
uin
ol
on
e-
re
si
st
an
t E
. 
c
o
li
total fluoroquinolone
Figure 1. Linear regression analysis of fluoroquinolone use (defined daily dose [DDD]/1000 patient-days), and the incidence of
fluoroquinolone-resistant E coli that cause nosocomial infection. (a) Parenteral moxifloxacin, parenteral levofloxacin, and
parenteral ciprofloxacin; (b) oral moxifloxacin, oral levofloxacin, and oral ciprofloxacin; (c) total moxifloxacin, total levofloxacin,
and total ciprofloxacin; (d) total fluoroquinolone.
Levofloxacin use and fluoroquinolone-resistant E coli 427aeruginosa isolates causing nosocomial infection was
correlated with levofloxacin use, but not with ciprofloxacin
use.13 Previous studies have shown that potential risk factors
for levofloxacin-resistant E coli infections included previous
levofloxacin use and recent hospitalization.1,14,15 However,
it is not clear whether controlling antibiotic use could
reduce the incidence of fluoroquinolone-resistant E coli.
An antimicrobial stewardship program was introduced in
the second half of 2007 to control levofloxacin use. Through
this program, fluoroquinolone resistance in P aeruginosawas
reduced in our hospital.13 Levofloxacin use was significantly
reduced after the introduction of the antimicrobial stew-
ardship program. The incidence of fluoroquinolone-resistant
E coli decreased after implementing the antimicrobial stew-
ardship program, which implies that decreased levofloxacin
use reduces fluoroquinolone resistance of E coli. Austin et al
hypothesized that a dramatic decrease in antibiotic usage is
necessary to reverse the trend towards resistance.16 This
hypothesis is compatible with the present results for E coli.
Among the fluoroquinolones used, moxifloxacin use was
negatively correlated with the incidence of fluoroquinolone-
resistant E coli, but this relationship was not statistically
significant. Ciprofloxacin and levofloxacin were both posi-
tively correlated with the incidence of fluoroquinolone-
resistant E coli, but only levofloxacin use, either parenteral
or oral, was significantly positively correlated with the
presence of fluoroquinolone-resistant E coli. Mutationprevention concentration (MPC), defined as the lowest
antibiotic concentration that prevents the growth of the
least susceptible single-step mutant present in a large
bacterial population,17 may explain this phenomenon. Anti-
biotic concentrations should bemaintained above theMPC to
avoid selecting for resistance.18,19 Linde et al reported that
the MPC of ciprofloxacin was two times lower than that of
levofloxacin.20 This suggests that E coli resistance is induced
moreeasilywith levofloxacin use thanwith ciprofloxacin use.
MacDougall et al reported that fluoroquinolone use,
particularly levofloxacin use, in the community showed
a stronger correlation than fluoroquinolone use in the
hospitals with fluoroquinolone resistance in E coli in the
hospitals.21 It is likely that a great proportion of nosocomial
E coli infections may originate from the community. In this
study, we found that, by controlling levofloxacin usage in
the hospital, it is possible to reduce the incidence of
fluoroquinolone-resistant E coli.
The rate of antibiotic resistance in a population can be
expressed in two ways: the percentage of nonsusceptible
(i.e. resistant and intermediately susceptible) isolates or
the number of nonsusceptible isolates per 1000 patient-days
(also referred to as the incidence). The latter appears to be
a more relevant indicator of resistance rate. Patients
receivingantibiotic treatmentmayhaveanecological impact
on all hospitalized patients.22,23 Rogues et al identified that,
compared to the percentage of resistant isolates, the
Table 2 Correlation between individual fluoroquinolone se and the incidence of fluoroquinolone-resistant Escherichia coli isolates that cause nosocomial infections
Prein ervetion period Postintervention period p
2004 2 05 2006 2007 2007 2008 2009 2010
Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec Jan-Jun Jul-Dec
Incidence of fluoroquinolone-
resistant E coli
0.18 0.21 0.30 0.26 0.27 0.26 0.31 0.22 0.22 0.24 0.17 0.24 0.15 0.16
Antibiotic use (DDD/1000PD)
Parenteral ciprofloxacin 16.16 13.02 16.83 10.84 10.00 12.08 10.24 6.25 8.40 7.21 10.20 7.98 7.06 6.74 0.296
Parenteral levofloxacin 0 0 4.92 6.79 9.00 8.45 8.80 5.45 3.65 3.61 1.67 1.12 2.10 1.00 0.002*
Parenteral moxifloxacin 1.11 1.86 1.06 0.00 0.00 0.00 0.37 1.54 3.07 4.28 3.71 3.48 3.41 1.89 0.382
Oral ciprofloxacin 12.47 14.15 14.20 14.62 12.58 14.67 13.75 12.47 14.43 15.47 13.88 17.10 15.24 12.84 0.627
Oral levofloxacin 6.67 7.05 13.63 6.04 10.15 9.29 8.09 1.22 2.68 6.52 4.14 2.35 3.59 3.46 0.018*
Oral moxifloxacin 0.00 0.00 0.00 0.00 0.00 0.00 0.20 0.53 0.17 0.53 2.32 3.18 2.53 3.05 0.421
Total ciprofloxacin 28.63 27.17 31.03 25.46 22.58 26.75 23.99 18.72 22.83 22.67 24.07 25.08 22.30 19.58 0.210
Total levofloxacin 6.67 7.05 18.54 12.83 19.15 17.74 16.89 6.67 6.33 10.12 5.81 3.47 5.69 4.46 0.001*
Total moxifloxacin 1.11 1.86 1.06 0.00 0.00 0.00 0.58 2.07 3.24 4.81 6.03 6.66 5.94 4.93 0.082
Total fluoroquinolone 36.41 36.08 50.64 38.29 41.73 44.49 41.45 27.46 32.40 37.60 35.92 35.22 33.93 28.97 0.005*
* statistically significant.
DDD/1000PD Z defined daily dose/1000 patient-days.
Table 3 The significant changes between the pre- and p stintervention periods
Preintervention period Postintervention period p-value
Mean SD Mean SD
Incidence of fluoroquinolone- resistant E coli
(isolates recovered per 1000 patient-days)
0.25472 0.04576 0.20129 0.04103 0.0402*
Antibiotics use (DDD/1000PD)
Parenteral ciprofloxacin 12.73933 2.77847 7.68995 1.32102 0.001*
Parenteral levofloxacin 5.42229 3.96458 2.65763 1.63747 0.0005*
Parenteral moxifloxacin 0.62947 0.72948 3.05274 0.99188 0.005*
Oral ciprofloxacin 13.77569 0.91030 14.48887 1.60827 0.327
Oral levofloxacin 8.70224 2.61611 3.42304 1.66782 0.0007*
Oral moxifloxacin 0.02900 0.07674 1.75832 1.29907 0.002*
Parenteral and oral Ciprofloxacin 26.51502 2.83971 22.17881 2.28762 0.008*
Parenteral and oral levofloxacin 14.12453 5.36748 6.08067 2.09814 0.006*
Parenteral and oral moxifloxacin 0.65847 0.72160 4.81106 1.64347 0.032*
Total fluoroquinolone 41.29802 5.12780 33.07054 3.71302 0.005*
* statistically significant.
DDD/1000PD Z defined daily dose/1000 patient-days; SD Z s ndard deviation.
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Levofloxacin use and fluoroquinolone-resistant E coli 429incidence of resistant isolates has a stronger correlation with
antibiotic usage.24 Therefore, in our study, the incidence
rate was used to investigate antibiotic resistance.
There are some limitations to our study. First, we only
discuss the impact of antibiotic consumption on bacterial
resistance. The emergence of bacterial resistance in
a hospital results from multiple factors, including the
occurrence of mutations, antibiotic use, and the various
infection control programs such as hand hygiene. Effective
infection control measurement could reduce at least 20% of
nosocomial infections.25 Therefore, we implemented an
infection control program focusing on controlling antibiotic
use, rather than environmental intervention. Second, only
small amounts of parenteral and oral moxifloxacin were
prescribed during the preintervention period, although oral
moxifloxacin has been available since the 2007 and paren-
teral moxifloxacin was not continuously available in the
preintervention period. Total moxifloxacin consumption has
increased gradually over the postintervention period. It was
found that use of moxifloxacin tended to be negatively
correlated with the incidence of fluoroquinolone-resistance
in E coli. An extension of the study period may be helpful to
clarify the relationship between moxifloxacin use and the
incidence of fluoroquinolone-resistance in E coli.
In conclusion, there is a significant correlation between
levofloxacin use and the incidence of fluoroquinolone-
resistant E coli isolates that cause nosocomial infections.
The incidence of nosocomial infections due to
fluoroquinolone-resistant E coli could be decreased by
reducing levofloxacin use in the hospital.
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